Berenberg Bank set a €20.00 ($23.26) price objective on Evotec (ETR:EVT) in a research note released on Wednesday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Separately, Deutsche Bank set a €23.00 ($26.74) price target on Evotec and gave the stock a neutral rating in a research report on Wednesday, April 10th.

Shares of EVT stock opened at €23.32 ($27.12) on Wednesday. The firm has a market cap of $3.47 billion and a PE ratio of 41.64. The company has a debt-to-equity ratio of 26.94, a quick ratio of 1.18 and a current ratio of 1.27. Evotec has a 12-month low of €12.18 ($14.16) and a 12-month high of €25.83 ($30.03).

About Evotec

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services.

Featured Story: What are retained earnings?

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with's FREE daily email newsletter.